Xenon Pharmaceuticals (XENE) Misses Q3 EPS by 25c

Xenon Pharmaceuticals (NASDAQ: XENE) reported Q3 EPS of ($0.27), $0.25 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $4.29 million versus the consensus estimate of $4.65 million.

For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c